Rare Daily Staff
Fulcrum Therapeutics named Alex Sapir, an industry veteran with more than 20 years of experience, as president and CEO and a member of its board of directors effective July 1, 2023.
Interim CEO and President Robert Gould will continue to serve as a member of the board of directors following the transition. Sapir joined Fulcrum as special advisor to the interim president and CEO in a part-time capacity before assuming his new role.
Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies.
“Alex brings a wealth of experience leading innovative companies through periods of strategic change, and a strong track record of delivering growth and enhanced value to patients, employees, and stockholders,” said Gould. “We have great confidence in his ability to shepherd our company through the next phase of our journey.”
Sapir most recently serving as CEO of ReViral, which Pfizer acquired last year. Previously, he served as president and CEO at Dova Pharmaceuticals, leading its transformation from a small, private, pre-commercial company to a 150-person, fully integrated, publicly traded biotech company (later acquired by Sobi, Inc.). Earlier in his career, Sapir was the executive vice president for marketing and sales at United Therapeutics and held commercial positions of increasing responsibility at GSK and other smaller healthcare companies.
Sapir received his BA in Economics from Franklin and Marshall College and his MBA from Harvard Business School where he concentrated in Finance and Strategy.
Stay Connected
Sign up for updates straight to your inbox.